IL217965A0 - Bicyclic heterocycles and their use as ccr2 receptor antagonists - Google Patents
Bicyclic heterocycles and their use as ccr2 receptor antagonistsInfo
- Publication number
- IL217965A0 IL217965A0 IL217965A IL21796512A IL217965A0 IL 217965 A0 IL217965 A0 IL 217965A0 IL 217965 A IL217965 A IL 217965A IL 21796512 A IL21796512 A IL 21796512A IL 217965 A0 IL217965 A0 IL 217965A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- bicyclic heterocycles
- ccr2 receptor
- ccr2
- heterocycles
- Prior art date
Links
- 102000004497 CCR2 Receptors Human genes 0.000 title 1
- 108010017312 CCR2 Receptors Proteins 0.000 title 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172408 | 2009-10-07 | ||
| PCT/EP2010/064770 WO2011042399A1 (en) | 2009-10-07 | 2010-10-05 | Bicyclic heterocycles and their use as ccr2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL217965A0 true IL217965A0 (en) | 2012-03-29 |
Family
ID=43105073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL217965A IL217965A0 (en) | 2009-10-07 | 2012-02-06 | Bicyclic heterocycles and their use as ccr2 receptor antagonists |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8471004B2 (enExample) |
| EP (1) | EP2486042B1 (enExample) |
| JP (1) | JP5559336B2 (enExample) |
| KR (1) | KR101451487B1 (enExample) |
| CN (1) | CN102574858B (enExample) |
| AU (1) | AU2010305495A1 (enExample) |
| BR (1) | BR112012008221A2 (enExample) |
| CA (1) | CA2774215A1 (enExample) |
| ES (1) | ES2455266T3 (enExample) |
| IL (1) | IL217965A0 (enExample) |
| IN (1) | IN2012DN00764A (enExample) |
| MX (1) | MX2012002390A (enExample) |
| WO (1) | WO2011042399A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| CN111423454B (zh) * | 2020-04-24 | 2021-06-22 | 苏州大学 | 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用 |
| CN113979889A (zh) * | 2021-11-09 | 2022-01-28 | 西安康福诺生物科技有限公司 | 一种双官能化聚乙二醇基胺的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740256A1 (de) | 1987-05-14 | 1988-12-08 | Bayer Ag | Thiazolo-hydantoine |
| MXPA03008109A (es) * | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| WO2004076411A2 (en) * | 2003-02-24 | 2004-09-10 | Merck & Co., Inc. | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
| EP1756089B1 (en) * | 2004-05-26 | 2008-10-22 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び／又は予防用の医薬組成物 |
| WO2007122103A1 (en) * | 2006-04-20 | 2007-11-01 | F. Hoffmann-La Roche Ag | Diazepan derivatives modulators of chemokine receptors |
| JP2010533672A (ja) | 2007-07-19 | 2010-10-28 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ヘテロシクリル化合物およびケモカインアンタゴニストとしてのそれらの使用 |
| CN101801952A (zh) | 2007-10-01 | 2010-08-11 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr受体拮抗剂的n-杂环联芳基甲酰胺类化合物 |
-
2010
- 2010-09-29 US US12/892,968 patent/US8471004B2/en not_active Expired - Fee Related
- 2010-10-05 KR KR1020127008883A patent/KR101451487B1/ko not_active Expired - Fee Related
- 2010-10-05 WO PCT/EP2010/064770 patent/WO2011042399A1/en not_active Ceased
- 2010-10-05 AU AU2010305495A patent/AU2010305495A1/en not_active Abandoned
- 2010-10-05 IN IN764DEN2012 patent/IN2012DN00764A/en unknown
- 2010-10-05 CN CN201080044805.6A patent/CN102574858B/zh not_active Expired - Fee Related
- 2010-10-05 MX MX2012002390A patent/MX2012002390A/es active IP Right Grant
- 2010-10-05 ES ES10766012.8T patent/ES2455266T3/es active Active
- 2010-10-05 CA CA2774215A patent/CA2774215A1/en not_active Abandoned
- 2010-10-05 BR BR112012008221A patent/BR112012008221A2/pt not_active IP Right Cessation
- 2010-10-05 JP JP2012532559A patent/JP5559336B2/ja not_active Expired - Fee Related
- 2010-10-05 EP EP10766012.8A patent/EP2486042B1/en not_active Not-in-force
-
2012
- 2012-02-06 IL IL217965A patent/IL217965A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN00764A (enExample) | 2015-06-26 |
| EP2486042A1 (en) | 2012-08-15 |
| MX2012002390A (es) | 2012-04-02 |
| BR112012008221A2 (pt) | 2016-03-08 |
| US8471004B2 (en) | 2013-06-25 |
| US20110082294A1 (en) | 2011-04-07 |
| EP2486042B1 (en) | 2014-01-22 |
| ES2455266T3 (es) | 2014-04-15 |
| CN102574858A (zh) | 2012-07-11 |
| JP5559336B2 (ja) | 2014-07-23 |
| KR20120051090A (ko) | 2012-05-21 |
| JP2013506701A (ja) | 2013-02-28 |
| KR101451487B1 (ko) | 2014-10-15 |
| CA2774215A1 (en) | 2011-04-14 |
| WO2011042399A1 (en) | 2011-04-14 |
| CN102574858B (zh) | 2015-06-24 |
| AU2010305495A1 (en) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3170A (en) | New CCR2 receptor antagonists and uses thereof | |
| ZA201203452B (en) | Cgrp receptor antagonists | |
| IL229507A0 (en) | Extrinsic opioid receptor antagonists and their uses | |
| ZA201105323B (en) | Agonists and antagonists of the sip5 receptor,and methods of uses thereof | |
| IL218502A0 (en) | Actriib antagonists and dosing and uses thereof | |
| ZA201202029B (en) | Androgen receptor antagonists and uses thereof | |
| PL2927224T3 (pl) | Antagoniści receptora | |
| IL215690A0 (en) | Thiazole derivatives and their use as p2y12 receptor antagonists | |
| IL213250A0 (en) | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 | |
| SI2491028T1 (sl) | Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1 | |
| IL214731A0 (en) | Uses of nk receptor antagonists | |
| IL225299A0 (en) | 7-Hydroxy-pyrazolo[1,5-a]pyrimidine compounds and their use as ccr2 receptor antagonists | |
| IL200781A0 (en) | Heterocycles as orexin antagonists | |
| IL217965A0 (en) | Bicyclic heterocycles and their use as ccr2 receptor antagonists | |
| IL200380A0 (en) | Mineralcorticoid receptor antagonists for the treatment of endometriosis | |
| IL217759A0 (en) | Pyrrolidine derivatives as nk3 receptor antagonists | |
| ZA201301561B (en) | 5-ht2b receptor antagonists | |
| IL213763A0 (en) | Pyrrolidine derivatives as nk3 receptor antagonists | |
| IL211803A0 (en) | Quinazoline derivatives as nk3 receptor antagonists | |
| ZA200906849B (en) | Mineralcorticoid receptor antagonists for the treatment of endomertriosis | |
| GB0705802D0 (en) | Novel receptor antagonists and their methods of use | |
| GB0711439D0 (en) | Novel receptor antagonists and their methods of use | |
| GB0709038D0 (en) | Novel receptor antagonists and their methods of use | |
| GB0900755D0 (en) | Ep4 receptor antagonists | |
| GB0900754D0 (en) | EP4 Receptor antagonists |